Accord Healthcare

As part of Accord Healthcare’s rapid portfolio expansion they have recently received different product approvals which enlarge and complement its oncology product portfolio

Press release   •   May 31, 2012 16:33 BST

Capecitabine Accord has been granted marketing authorization through Centralized Procedure in April. Capecitabine is the generic version of Xeloda® and it is indicated for metastatic breast cancer and colorectal cancer. This approval represents to Accord its 7th Centralized approval and the 119th overall EU approvals. Capecitabine Accord will be available in tablets of 150mg, 300mg and 500mg tablets.

As Part of the Intas Group, Accord Healthcare is a young and dynamic pharmaceutical company, involved in the development, manufacturing and distribution of pharmaceutical products to over 50 markets around the world.